Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma.
neoadjuvant chemotherapy
patient selection
penile cancer
regression-tree
squamous cell carcinoma
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
accepted:
05
03
2020
pubmed:
17
3
2020
medline:
31
10
2020
entrez:
17
3
2020
Statut:
ppublish
Résumé
To identify predictors of poor overall survival (OS) amongst patients with penile squamous cell carcinoma (pSCC) with clinical inguinal lymphadenopathy (cN+), in order to define the best candidates for neoadjuvant chemotherapy (NAC). Using an international, multicentre database of 924 patients with pSCC, we identified 334 men who harboured cN+ with available clinical and follow-up data. Lymph node involvement was defined either by the presence of palpable inguinal node disease or by preoperative computed tomography (CT) assessment. Fluorine-18 fluorodeoxyglucose positron-emission tomography ( Overall, 120 (35.9%), 152 (45.5%), and 62 (18.6%) patients harboured cN1, cN2, and cN3 disease. Patients with pSCC with cN3 or cN2 and inguinal and pelvic 18F-FDG-PET/CT scan detected disease had higher 24-month OM rates according to our regression-tree model. NAC was associated with improved OS only in these subgroups of patients. Our novel decision model may help to stratify cN+ patients, and identify those who most likely will benefit from NAC prior to radical surgical resection.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
867-875Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.
Références
Kamel MH, Bissada N, Warford R, Farias J, Davis R. Organ sparing surgery for penile cancer: a systematic review. J Urol 2017; 198: 770-9
Lont AP, Kroon BK, Gallee MPW, van Tinteren H, Moonen LMF, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007; 177: 947-52
Chipollini J, Necchi A, Spiess PE. Outcomes for patients with node-positive penile cancer: impact of perioperative systemic therapies and the importance of surgical intervention. Eur Urol 2018; 74: 241-2
Chipollini J, Azizi M, Lo Vullo S et al. Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU Int 2020; 125: 82-8
Leijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol 2007; 52: 488-94
Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007; 177: 1335-8
Haas GP, Blumenstein BA, Gagliano RG et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999; 161: 1823-5
Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 2006; 98: 1225-7
Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 1990; 65: 433-8
Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992; 147: 630-2
Pagliaro LC, Williams DL, Daliani D et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28: 3851-7
Meeting Library | Survival analyses of adjuvant or neoadjuvant combination of a taxane plus cisplatin and 5-fluorouracil (T-PF) in patients with bulky nodal metastases from squamous cell carcinoma of the penis (PSCC): Results of a single high-volume center. [Internet]. Available at: https://meetinglibrary.asco.org/record/90280/abstract. Accessed November 2019
Nicholson S, Hall E, Harland SJ et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer 2013; 109: 2554-9
Necchi A, Lo Vullo S, Perrone F et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int 2018; 121: 348-56
Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int 2016; 117: 118-25
Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015; 67: 142-50
Graafland NM, Leijte JAP, Valdés Olmos RA, Hoefnagel CA, Teertstra HJ, Horenblas S. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. Eur Urol 2009; 56: 339-45
Necchi A, Lo Vullo S, Mariani L et al. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: a retrospective multicenter study. Urol Oncol 2019; 37: 531.e7-15
Johnstone PA, Boulware D, Djajadiningrat R et al. Primary penile cancer: the role of adjuvant radiation therapy in the management of extranodal extension in lymph nodes. Eur Urol Focus 2019; 5: 737-41
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4.
Horenblas S. Lymphadenectomy for squamous cell carcinoma of the penis. Part 2: the role and technique of lymph node dissection. BJU Int 2001; 88: 473-83
Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. Eur Urol 2009; 55: 1075-88
Jakobsen JK, Alslev L, Ipsen P et al. DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer - a national study from Denmark. BJU Int 2016; 118: 102-11
Kang BJ, Lee JH, Yoo IR et al. Clinical significance of incidental finding of focal activity in the breast at 18F-FDG PET/CT. AJR Am J Roentgenol 2011; 197: 341-7
Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun 2004; 25: 651-6
Gandaglia G, Soligo M, Battaglia A et al. Which patients with clinically node-positive prostate cancer should be considered for radical prostatectomy as part of multimodal treatment? The impact of nodal burden on long-term outcomes. Eur Urol 2019; 75: 817-25
Loh WY, He X, Man M. A regression tree approach to identifying subgroups with differential treatment effects. Stat Med 2015; 34: 1818-33
Therneau T, Atkinson B, Port BR (producer of the initial R, maintainer 1999-2017). rpart: Recursive Partitioning and Regression Trees [Internet], 2019. Available at: https://CRAN.R-project.org/package=rpart. Accessed February 2020
Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer 2015; 13: 44-9
Xu J, Li G, Zhu SM et al. Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis. BMC Cancer 2019; 19: 625
Canter DJ, Nicholson S, Watkin N, Hall E, Pettaway C, InPACT Executive Committee. The International Penile Advanced Cancer Trial (InPACT): rationale and current status. Eur Urol Focus 2019; 5: 706-9
Schlenker B, Scher B, Tiling R et al. Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol 2012; 30: 55-9
Williams SB, Ray-Zack MD, Hudgins HK, et al. Impact of centralizing care for genitourinary malignancies to high-volume providers: A systematic review. Eur Urol Oncol. 2019; 2(3): 265-73
Graafland NM, Teertstra HJ, Besnard APE, van Boven HH, Horenblas S. Identification of high risk pathological node positive penile carcinoma: value of preoperative computerized tomography imaging. J Urol 2011; 185: 881-7